

VALDIG General Assembly at ILC 2019 in Vienna, Wednesday 10th April, 18.00-19.00, Room Schubert 3 Program

1. Steering committee renewal:

Members leaving:

- Juan-Carlos Garcia-Pagan
- Laura Rubbia-Brandt
- Markus Peck
- Joeffrey Schouten
- Jonel Trebicka,

Current steering committee:

Chair

Andrea De Gottardi, Switzerland

Secretary

Pierre-Emmanuel Rautou, France

Vice Secretary

Virginia Hernandez Gea, Spain

ERN-Liaison

Aurélie Plessier, France

Sarwa Darwish Murad, NL until 2021

Laure Elkrief, CH until 2023

Filipe Nery, PRT until 2023

Valérie Paradis, FRA until 2023

Marco Senzolo, ITA until 2021

Akash Shukla, IND until 2021

2. Finances

570 CHF have been spent over the last year to maintain the VALDIG website.

The remaining budget is 31 300 €.

3. VALDIG as a new EASL Consortium

VALDIG has been recognized officially as an EASL consortium. All EASL consortia appear on EASL website:

4. Publications over the last year

L. Elkrief et al. *Abdominal surgery in patients with idiopathic noncirrhotic portal hypertension: a multicenter retrospective study* (**Hepatology**)

A. De Gottardi et al.: *Porto-sinusoidal vascular disease: proposal and description of a novel entity* (**Lancet Gastroenterology and Hepatology**)

F. Andrade et al.: *Pregnancy in idiopathic non-cirrhotic portal hypertension: A multicentric study on maternal and fetal management and outcome* (**J. Hepatol**)

[Novel publication rules:](#) the term “VALDIG, an EASL consortium” should be added after authors of papers resulting from a collaboration between members of VALDIG [open to all VALDIG members.](#)

In case of involvement of multiple investigators, the option of “VALDIG investigators” might be used to acknowledge persons involved.

5. EASL Clinical practice guidelines on "Management of coagulation status and bleeding risk in patients with liver diseases"

EASL has decided to launch these guidelines. Writing is ongoing.
It will follow a Delphi process.

6. VALDIG in ERN Rare Liver

The objectives of the ERN's are to:

1. improve clinical care by development of guidelines, training, sharing of knowledge.
2. secure involvement of key stakeholders including patients and patient organisations.
3. develop research activities as well as clinical trials to improve disease understanding.
4. implement new IT systems to enable clinical collaboration.

Structure 3 pillars:

Autoimmune Liver Disease: (Lead: Ansgar Lohse)

Primary Biliary Cholangitis (PBC, formerly Primary Biliary Cirrhosis)

Autoimmune Hepatitis (AIH)

Primary Sclerosing Cholangitis (PSC)

IgG4 Disease

Metabolic, Biliary Atresia & Related Disease: (Lead: Ekkehard Sturm)

Genetic Cholestatic Disease

Biliary Atresia

Choledochal Cyst

Alpha-1-Antitrypsin Liver Disease

Wilson's Disease

Structural Liver Disease: (Lead: Joost Drenth)

Cystic Liver Disease

Vascular Liver Disease

Intrahepatic Cholangiocarcinoma

ERN rare liver today

- **full members** from Belgium, Denmark, France, Germany, Italy, Netherlands, Poland, Portugal, Spain, Sweden and UK.
- **affiliated member** in Norway and additional applications were sent from Cyprus, Estonia, Hungary and Latvia. Centres that have applied already receive emails from ERN.
- **collegiate partnership**: Centres from France, Germany, Italy, Lithuania, Poland, Romania and Switzerland have sent their applications for collegiate partnership.

Missing centres from Austria, Bulgaria, Czech republic, Finland, Croatia, Ireland, Lithuania, Luxembourg, Malta, Slovakia, Slovenia.

Currently VALDIG members also ERN rare liver members:

- Juan-Carlos Garcia-Pagan
- Vincenzo La Mura
- Aurélie Plessier
- Marco Senzolo

7. Ongoing studies:

- Medically assisted reproduction in women with vascular liver diseases (*A Payancé*)
- Fontan-associated liver disease (*A Albillos & L Téllez*)
- Abdominal surgery in patients with extra-hepatic portal vein obstruction (*L Elkrief & PE Rautou*)
- PNH and splanchnic vein thrombosis (*A. Plessier*)
- Idiopathic noncirrhotic portal hypertension and liver transplantation (OLT), outcome and prognosis factors (*M. Magaz Martinez*)
- Abernethy malformation (*J-C. Garcia-Pagan*)

8. Registry and ERN

It has to be decided how to join ERN without losing the effort made to create the current VALDIG registry.

A Plessier and A de Gottardi will go to Hamburg on June 11 to elaborate a solution with ERN to safely transfer data and to have the possibility of extracting data and use them.